AR072777A1 - Formas solidas de clorhidrato de bendamustina - Google Patents
Formas solidas de clorhidrato de bendamustinaInfo
- Publication number
- AR072777A1 AR072777A1 ARP090101039A ARP090101039A AR072777A1 AR 072777 A1 AR072777 A1 AR 072777A1 AR P090101039 A ARP090101039 A AR P090101039A AR P090101039 A ARP090101039 A AR P090101039A AR 072777 A1 AR072777 A1 AR 072777A1
- Authority
- AR
- Argentina
- Prior art keywords
- bendamustine
- bendamustine hydrochloride
- chlorhydrate
- solid forms
- degrees 2theta
- Prior art date
Links
- 239000007787 solid Substances 0.000 title abstract 3
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 title 1
- 229960002707 bendamustine Drugs 0.000 title 1
- ZHSKUOZOLHMKEA-UHFFFAOYSA-N 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 ZHSKUOZOLHMKEA-UHFFFAOYSA-N 0.000 abstract 6
- 229960001215 bendamustine hydrochloride Drugs 0.000 abstract 6
- 239000000203 mixture Substances 0.000 abstract 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3975208P | 2008-03-26 | 2008-03-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR072777A1 true AR072777A1 (es) | 2010-09-22 |
Family
ID=41051023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090101039A AR072777A1 (es) | 2008-03-26 | 2009-03-23 | Formas solidas de clorhidrato de bendamustina |
Country Status (12)
| Country | Link |
|---|---|
| US (9) | US20090264488A1 (https=) |
| EP (2) | EP2271315B1 (https=) |
| JP (1) | JP5536753B2 (https=) |
| CN (3) | CN101980698B (https=) |
| AR (1) | AR072777A1 (https=) |
| CA (1) | CA2718939A1 (https=) |
| CL (1) | CL2009000742A1 (https=) |
| ES (1) | ES2605205T3 (https=) |
| HK (1) | HK1220966A1 (https=) |
| MX (2) | MX339878B (https=) |
| TW (1) | TWI472515B (https=) |
| WO (1) | WO2009120386A2 (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8436190B2 (en) * | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
| EP2583670A1 (en) * | 2007-10-09 | 2013-04-24 | US Worldmeds LLC | Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents |
| AR072777A1 (es) | 2008-03-26 | 2010-09-22 | Cephalon Inc | Formas solidas de clorhidrato de bendamustina |
| CA2735899A1 (en) * | 2008-09-25 | 2010-04-01 | Cephalon, Inc. | Liquid formulations of bendamustine |
| UA107186C2 (xx) * | 2008-12-03 | 2014-12-10 | Тверді форми дозування бендамустину | |
| WO2010144675A1 (en) * | 2009-06-10 | 2010-12-16 | Plus Chemicals Sa | Polymorphs of bendamustine hcl and processes for preparation thereof |
| EP2516404A4 (en) | 2009-12-23 | 2013-04-17 | Reddys Lab Ltd Dr | PREPARATION OF BENDAMUSTINE AND ITS SALTS |
| SMT201700043T1 (it) | 2010-01-28 | 2017-03-08 | Eagle Pharmaceuticals Inc | Formulazioni di bendamustina |
| JO3659B1 (ar) | 2010-06-02 | 2020-08-27 | Astellas Deutschland Gmbh | أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية |
| JO3587B1 (ar) | 2010-06-02 | 2020-07-05 | Astellas Deutschland Gmbh | أشكال جرعات بينداموستين عن طريق الفم |
| CN101948437B (zh) * | 2010-06-28 | 2012-08-29 | 江苏奥赛康药业股份有限公司 | 一种盐酸苯达莫司汀的精制方法 |
| EP2635558A4 (en) * | 2010-11-01 | 2014-08-06 | Shilpa Medicare Ltd | PROCESS FOR PREPARING BENDAMUSTINE HYDROCHLORIDE MONOHYDRATE |
| US20140142153A1 (en) * | 2011-01-25 | 2014-05-22 | Dr. Reddy's Laboratories, Inc. | Bendamustine formulations |
| AU2012212622A1 (en) * | 2011-01-31 | 2013-07-11 | Cephalon, Inc. | Methods for the preparation of bendamustine |
| EP2760842B1 (en) | 2011-09-26 | 2016-11-16 | Fresenius Kabi Oncology Ltd | An improved process for the preparation of bendamustine hydrochloride |
| CN102351799B (zh) * | 2011-10-24 | 2014-02-26 | 江苏奥赛康药业股份有限公司 | 一种盐酸苯达莫司汀晶型及其制备方法 |
| EP2617716A1 (en) | 2012-01-18 | 2013-07-24 | Arevipharma GmbH | Process for the preparation of bendamustine hydrochloride and related compounds |
| JP6250628B2 (ja) | 2012-03-20 | 2017-12-20 | イーグル・ファーマシューティカルズ・インコーポレーテッド | ベンダムスチンの製剤 |
| US20230241218A1 (en) * | 2012-07-10 | 2023-08-03 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
| CN104271135B (zh) | 2012-03-20 | 2017-05-17 | 赛多斯有限责任公司 | 在要求减少施用容量的患者中治疗苯达莫司汀响应性状况的方法 |
| WO2013150020A1 (en) | 2012-04-03 | 2013-10-10 | Synthon Bv | Process for making bendamustine |
| DK2656843T3 (en) | 2012-04-26 | 2015-04-20 | Helmut Schickaneder | Esters of bendamustine and related compounds, and medical use thereof |
| US9801859B2 (en) * | 2012-09-18 | 2017-10-31 | Innopharma Licensing, Llc | Bendamustine formulations |
| KR20150086308A (ko) | 2012-11-12 | 2015-07-27 | 이그니타, 인코포레이티드 | 벤다무스틴 유도체 및 그의 사용 방법 |
| EP2958554B1 (en) | 2013-02-19 | 2018-06-06 | Synthon BV | Stable compositions of bendamustine |
| US9315469B2 (en) | 2013-03-14 | 2016-04-19 | Johnson Matthey Public Limited Company | Process for drying bendamustine hydrochloride monohydrate |
| WO2014170769A2 (en) * | 2013-04-15 | 2014-10-23 | Shilpa Medicare Limited | Bendamustine lyophilized pharmaceutical compositions |
| EP3043648B1 (en) | 2013-08-27 | 2023-09-20 | Vasilios VOUDOURIS | Bendamustine pharmaceutical compositions |
| EP3116481A1 (en) | 2014-03-13 | 2017-01-18 | Vasilios VOUDOURIS | Bendamustine solid dispersions and continuous infusion |
| EP2985038A1 (en) | 2014-08-12 | 2016-02-17 | Azad Pharma AG | Lyophilized API preparation |
| US10342769B2 (en) | 2014-11-14 | 2019-07-09 | Navinta Iii Inc | Carmustine pharmaceutical composition |
| US9603930B2 (en) | 2014-12-04 | 2017-03-28 | Navinta, Llc | Liquid bendamustine formulation |
| ES2889902T3 (es) * | 2015-06-09 | 2022-01-14 | Rebiotix Inc | Métodos de fabricación de composiciones para terapia de restauración de la microbiota (TRM) |
| US10905677B2 (en) | 2016-08-31 | 2021-02-02 | Navinta, Llc | Bendamustine solution formulations |
| US11826466B2 (en) | 2016-08-31 | 2023-11-28 | Navinta, Llc | Bendamustine solution formulations |
| RU2020115024A (ru) | 2017-10-05 | 2021-11-08 | Тьюб Фармасьютикалз Гмбх | Препараты бендамустина для перорального введения |
| CN111093654B (zh) * | 2017-11-07 | 2023-03-10 | 江苏恒瑞医药股份有限公司 | 一种盐酸苯达莫司汀的晶体及其制备方法 |
| EA037673B1 (ru) * | 2018-07-04 | 2021-04-29 | Тютор С.А.С.И.Ф.И.А. | Способ получения фармацевтической композиции, содержащей бендамустин, фармацевтическая композиция бендамустина |
| EP3836921B1 (en) | 2018-08-17 | 2025-10-08 | Hospira Australia Pty Ltd | Liquid bendamustine pharmaceutical compositions |
| WO2022103639A1 (en) | 2020-11-16 | 2022-05-19 | Orcosa Inc. | Methods of treating autoimmune or inflammatory conditions with cannabidiol or its derivatives/analogs |
| US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
| JP2024537431A (ja) | 2021-10-22 | 2024-10-10 | プロジェクト ファーマシューティクス ゲーエムベーハー | 液状薬学的製剤 |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE34727C (de) | Ch. H. TH. HAVEMANN in Paris, 16 rue Bleue | Verfahren zur direkten Gewinnung metallischen Bleis | ||
| DE80967C (https=) | ||||
| DE293808C (https=) | ||||
| DE159877C (https=) * | ||||
| DD80967A (https=) | ||||
| DE159289C (https=) | 1903-10-08 | 1905-03-16 | ||
| DD34727A1 (de) | 1963-12-21 | 1964-12-28 | Dietrich Krebs | Verfahren zur Herstellung von 1-Stellung substituierten [5-Bis-(chloräthyl)-amino-benzimidazolyl-(2)]-alkancarbonsäuren |
| YU33730B (en) | 1967-04-18 | 1978-02-28 | Farmaceutici Italia | Process for preparing a novel antibiotic substance and salts thereof |
| US4012448A (en) | 1976-01-15 | 1977-03-15 | Stanford Research Institute | Synthesis of adriamycin and 7,9-epiadriamycin |
| DD159289A1 (de) | 1981-06-01 | 1983-03-02 | Uwe Olthoff | Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen |
| DD159877A1 (de) * | 1981-06-12 | 1983-04-13 | Wolfgang Krueger | Verfahren zur herstellung von 4-[1-methyl-5-bis(2-chloraethyl)amino-benzimidazolyl-2]-buttersaeure |
| IT1153974B (it) | 1982-09-23 | 1987-01-21 | Erba Farmitalia | Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento |
| US5227374A (en) | 1982-11-12 | 1993-07-13 | Mead Johnson & Company | Lyophilized cyclophosphamide |
| US4537883A (en) | 1982-11-12 | 1985-08-27 | Mead Johnson & Company | Lyophilized cyclophosphamide |
| US4659699A (en) | 1983-08-22 | 1987-04-21 | Cetus-Ben Venue Therapeutics | Process for freeze drying cyclophosphamide |
| US5183746A (en) | 1986-10-27 | 1993-02-02 | Schering Aktiengesellschaft | Formulation processes for pharmaceutical compositions of recombinant β- |
| US5204335A (en) * | 1986-10-31 | 1993-04-20 | Asta Pharma Aktiengesellschaft | Ifosfamide lyophilisate and process for its preparation |
| US4879286A (en) | 1987-01-28 | 1989-11-07 | Lyphomed, Inc. | Cyclophosphamide |
| DE3907079A1 (de) | 1988-03-19 | 1989-09-28 | Asta Pharma Ag | Ifosfamid-mesna-lyophilisat und verfahren zu dessen herstellung |
| EP0334083B1 (de) | 1988-03-19 | 1991-07-24 | ASTA Pharma Aktiengesellschaft | Ifosfamid-Mesna-Lyophilisat und Verfahren zu dessen Herstellung |
| US5036060A (en) | 1988-07-25 | 1991-07-30 | Fujisawa Usa, Inc. | Cyclophosphamide |
| CA2001552C (en) | 1988-11-14 | 1997-07-22 | The Upjohn Company | Cyclophosphamide - sodium bicarbonate lyophilizates |
| US5066647A (en) | 1989-04-20 | 1991-11-19 | Erbamont, Inc. | Cyclophosphamide - alanine lyophilizates |
| US5051257A (en) | 1989-05-09 | 1991-09-24 | Pietronigro Dennis D | Antineoplastic solution and method for treating neoplasms |
| DD293808A5 (de) | 1990-04-23 | 1991-09-12 | Zi Fuer Mikrobiologie Uns Experimentelle Therapie,De | Verfahren zur herstellung von (5-[bis(2-chlorethyl)amino]-1-methyl-benzimidazolyl(2)ethansaeurealkylestern |
| US5268368A (en) | 1991-05-17 | 1993-12-07 | Erbamont, Inc. | Cyclophosphamide--amino acid lyophilizates |
| US5227373A (en) * | 1991-10-23 | 1993-07-13 | Bristol-Myers Squibb Co. | Lyophilized ifosfamide compositions |
| US5192743A (en) | 1992-01-16 | 1993-03-09 | Genentech, Inc. | Reconstitutable lyophilized protein formulation |
| DK0752248T3 (da) * | 1992-11-13 | 2000-11-13 | Idec Pharma Corp | Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig |
| US5418223A (en) | 1993-05-20 | 1995-05-23 | Erbamont, Inc. | Method for lyophilization of cyclophosphamide and product |
| US5595721A (en) * | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| DK0725642T3 (da) * | 1993-10-27 | 2000-05-29 | Upjohn Co | Stabiliseret prostaglandin E1 |
| US5561121A (en) | 1993-11-09 | 1996-10-01 | American Cyanamid Company | Stable lyophilized thiotepa composition |
| US5955504A (en) | 1995-03-13 | 1999-09-21 | Loma Linda University Medical Center | Colorectal chemoprotective composition and method of preventing colorectal cancer |
| DE19529057B4 (de) * | 1995-08-08 | 2007-12-13 | Baxter Healthcare S.A. | Ifosfamid-Lyophilisat-Zubereitungen |
| EP0859779A4 (en) | 1995-08-31 | 2000-04-12 | Smithkline Beecham Corp | INTERLEUKIN CONVERSION ENZYME AND APOPTOSIS |
| ATE225343T1 (de) | 1995-12-20 | 2002-10-15 | Hoffmann La Roche | Matrix-metalloprotease inhibitoren |
| US6261537B1 (en) | 1996-10-28 | 2001-07-17 | Nycomed Imaging As | Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors |
| US6034256A (en) * | 1997-04-21 | 2000-03-07 | G.D. Searle & Co. | Substituted benzopyran derivatives for the treatment of inflammation |
| US20040072889A1 (en) * | 1997-04-21 | 2004-04-15 | Pharmacia Corporation | Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia |
| US6077850A (en) * | 1997-04-21 | 2000-06-20 | G.D. Searle & Co. | Substituted benzopyran analogs for the treatment of inflammation |
| WO1999001118A2 (en) | 1997-07-01 | 1999-01-14 | Atherogenics, Inc. | Antioxidant enhancement of therapy for hyperproliferative conditions |
| GB9803448D0 (en) | 1998-02-18 | 1998-04-15 | Pharma Mar Sa | Pharmaceutical formulation |
| WO2000002555A1 (en) * | 1998-07-09 | 2000-01-20 | Nardella Francis A | Methods and compositions for the treatment of chronic lymphocytic leukemia |
| US6689600B1 (en) | 1998-11-16 | 2004-02-10 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
| US5972912A (en) * | 1998-12-17 | 1999-10-26 | S.P. Pharmaceuticals | Method for lyophilizing ifosfamide |
| US6569402B1 (en) * | 1998-12-18 | 2003-05-27 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
| US6380210B1 (en) * | 1999-04-02 | 2002-04-30 | Neurogen Corporation | Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors |
| US6545034B1 (en) * | 1999-07-23 | 2003-04-08 | The Regents Of The University Of California | Use of etodolac for the treatment of chronic lymphocytic leukemia |
| DE10016077A1 (de) | 2000-03-31 | 2001-12-13 | Cellcontrol Biomedical Lab Gmb | Verfahren und Vorrichtung zum automatischen Nachweisen einer Wirkung eines zellbeeinflussenden Mittels auf lebende Zellen |
| AUPQ849900A0 (en) | 2000-06-30 | 2000-07-27 | Dbl Australia Pty Ltd. | Injectable composition |
| US20040152672A1 (en) * | 2000-08-09 | 2004-08-05 | Carson Dennis A. | Indole compounds useful for the treatment of cancer |
| CN1487936A (zh) * | 2000-12-11 | 2004-04-07 | ����ҩƷ��ҵ��ʽ���� | 具有改进吸收性能的药物组合物 |
| PL362979A1 (en) * | 2000-12-11 | 2004-11-02 | Takeda Chemical Industries, Ltd. | Medicinal compositions improved in solublity in water |
| WO2002080996A1 (de) * | 2001-04-03 | 2002-10-17 | Franz Herbst | Medizinisches implantat und verfahren zu seiner herstellung |
| CN1568166A (zh) * | 2001-10-15 | 2005-01-19 | 荷姆泰克股份有限公司 | 预防再狭窄的涂层支架 |
| US6613927B1 (en) * | 2002-02-08 | 2003-09-02 | American Pharmaceutical Partners, Inc. | Sterile lyophilized ifosfamide and associated methods |
| DE10306724A1 (de) | 2002-02-28 | 2003-09-18 | G O T Therapeutics Gmbh | Vesikuläre Verkapselung von Bendamustin |
| US6780324B2 (en) | 2002-03-18 | 2004-08-24 | Labopharm, Inc. | Preparation of sterile stabilized nanodispersions |
| AU2003221517B2 (en) | 2002-03-22 | 2010-02-18 | Christian Straka | Cytocapacity test |
| EP1495124A2 (en) | 2002-04-17 | 2005-01-12 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Smac-peptides as therapeutics against cancer and autoimmune diseases |
| EP1354952A1 (en) | 2002-04-17 | 2003-10-22 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Smac-peptides as therapeutics against cancer and autoimmune diseases |
| EP1501565B1 (de) | 2002-05-09 | 2006-11-02 | Hemoteq GmbH | Verbindungen und verfahren zur hemokompatiblen beschichtung von oberflächen |
| AU2003258061A1 (en) * | 2002-08-02 | 2004-02-23 | Salmedix, Inc. | Therapeutic inhibitionof protein kinases in cancer cells |
| BR0315194A (pt) | 2002-10-31 | 2005-08-23 | Umd Inc | Composições terapêuticas para liberação de droga para a, e através da, cobertura epitelial |
| DE10304403A1 (de) | 2003-01-28 | 2004-08-05 | Röhm GmbH & Co. KG | Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung |
| EP1444989A1 (en) | 2003-02-07 | 2004-08-11 | Giorgio Dr. Stassi | Sensitizing cells for apoptosis by selectively blocking cytokines |
| CA2516191A1 (en) * | 2003-02-14 | 2004-09-02 | Salmedix, Inc | Compositions and methods for the detection and treatment of methylthioadenosine phosphorylase deficient cancers |
| KR20060052880A (ko) * | 2003-07-25 | 2006-05-19 | 와이어쓰 | 동결건조된 ｃｃｉ- 779 제형 |
| MX2007005361A (es) * | 2004-11-05 | 2008-01-11 | Cephalon Inc | Tratamientos para cancer. |
| PT1814517E (pt) | 2004-11-22 | 2010-11-03 | Venus Remedies Ltd | Formulação parentérica líquida não aquosa de aceclofenac |
| EP1674081A1 (de) * | 2004-12-23 | 2006-06-28 | KTB Tumorforschungsgesellschaft mbH | Herstellung von lipidbasierten Nanopartikeln unter Einsatz einer dualen asymmetrischen Zentrifuge |
| UA94036C2 (ru) * | 2005-01-14 | 2011-04-11 | Сефалон, Инк. | Фармацевтическая композиция бендамустина, предназначенная для лиофилизации |
| US8436190B2 (en) * | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
| US7872050B2 (en) | 2005-03-14 | 2011-01-18 | Yaupon Therapeutics Inc. | Stabilized compositions of volatile alkylating agents and methods of using thereof |
| US20080200383A1 (en) | 2005-04-08 | 2008-08-21 | Amylin Pharmaceuticals, Inc. | Pharmaceutical Formulations Comprising Incretin Peptide and Aprotic Polar Solvent |
| US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| ITUD20070130A1 (it) | 2007-07-23 | 2009-01-24 | C M E Spa Sa | Macchina e procedimento per la produzione di elementi strutturali per l'edilizia in materiale cementizio aventi uno o piu' inserti in materiale polimerico |
| AR072777A1 (es) | 2008-03-26 | 2010-09-22 | Cephalon Inc | Formas solidas de clorhidrato de bendamustina |
| CA2735899A1 (en) | 2008-09-25 | 2010-04-01 | Cephalon, Inc. | Liquid formulations of bendamustine |
| JP2012525387A (ja) | 2009-04-28 | 2012-10-22 | セファロン、インク． | ベンダムスチンの経口製剤 |
-
2009
- 2009-03-23 AR ARP090101039A patent/AR072777A1/es not_active Application Discontinuation
- 2009-03-26 TW TW098110003A patent/TWI472515B/zh active
- 2009-03-26 MX MX2013011045A patent/MX339878B/es unknown
- 2009-03-26 MX MX2010010398A patent/MX2010010398A/es active IP Right Grant
- 2009-03-26 EP EP09723661.6A patent/EP2271315B1/en active Active
- 2009-03-26 CN CN2009801107677A patent/CN101980698B/zh active Active
- 2009-03-26 EP EP16188467.1A patent/EP3150197A1/en not_active Withdrawn
- 2009-03-26 JP JP2011501846A patent/JP5536753B2/ja active Active
- 2009-03-26 WO PCT/US2009/001956 patent/WO2009120386A2/en not_active Ceased
- 2009-03-26 CA CA2718939A patent/CA2718939A1/en not_active Abandoned
- 2009-03-26 US US12/411,929 patent/US20090264488A1/en not_active Abandoned
- 2009-03-26 CL CL2009000742A patent/CL2009000742A1/es unknown
- 2009-03-26 CN CN201610027378.XA patent/CN105693620A/zh active Pending
- 2009-03-26 CN CN201310415249.4A patent/CN103550159B/zh active Active
- 2009-03-26 ES ES09723661.6T patent/ES2605205T3/es active Active
-
2011
- 2011-11-22 US US13/301,979 patent/US8445524B2/en active Active
-
2013
- 2013-05-01 US US13/874,575 patent/US8669279B2/en active Active
-
2014
- 2014-03-07 US US14/200,738 patent/US8883836B2/en active Active
- 2014-11-03 US US14/531,023 patent/US20150051258A1/en not_active Abandoned
-
2016
- 2016-02-17 US US15/045,523 patent/US9533955B2/en active Active
- 2016-07-26 HK HK16108932.6A patent/HK1220966A1/zh unknown
- 2016-11-23 US US15/359,777 patent/US10039750B2/en active Active
-
2018
- 2018-07-17 US US16/037,560 patent/US10517852B2/en active Active
-
2019
- 2019-11-18 US US16/686,751 patent/US20200323824A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR072777A1 (es) | Formas solidas de clorhidrato de bendamustina | |
| GT200600371A (es) | Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas | |
| CR11267A (es) | Preparacion solida que contiene alogliptina y clorhidrato de metformina | |
| AR063347A1 (es) | Formas cristalinas de docetaxel y proceso para su preparacion | |
| PE20140698A1 (es) | Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2, 4-diamina | |
| MX347804B (es) | Formas solidas de (r)-1(2,2-difluorobenzo[d] [1,3]dioxol-5-il)-n-( 1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il) -1h-indol-5-il) ciclopropanocarboxamida. | |
| NO20083895L (no) | Anti-IGF-1R human monoklonalantibody formulering | |
| AR064099A1 (es) | Forma cristalina del hemihidrato de 1-(beta-d-glucopiranosil)-4-metil-3-[5-(4-fluorofenil)-2-tienilmetil]benceno | |
| EP1776225A4 (en) | NANOSTRUCTURE POST-TREATMENT ENCODING: COMPOSITIONS, DEVICES AND SYSTEMS THEREWITH | |
| CY1115932T1 (el) | Σκευασμα αντισωματος | |
| CR11029A (es) | Anticuerpos en contra de erbb3 y usos de los mismos | |
| MX336875B (es) | Sal de besilato de un inhibidor de tirosina cinasa de bruton (btk). | |
| UY29856A1 (es) | Forma cristalina 8d del clorhidrato de la ivabradina, su procedimiento de preparación, y las composiciones farmaceuticas que la contienen | |
| CL2008003016A1 (es) | Composicion para tratamiento de lavanderia que comprende una base de tratamiento de lavanderia y desde 0,01 a 10% en peso de particulas de film laminar concavas coloreadas. | |
| AR082804A1 (es) | Formas cristalinas de un inhibidor del factor xa | |
| GT200600227A (es) | Formas solidas cristalinas de tigeciclina y metodos para preparar las mismas | |
| DK1968948T3 (da) | Hidtil ukendt hydrogensulfatsalt | |
| AR098888A1 (es) | Composición para el cuidado oral | |
| AR093738A1 (es) | Formas solidas que comprenden inhibidores de ns5a de hcv, sus composiciones y sus usos | |
| FI20055630L (fi) | Kasvonaamio | |
| CO6430482A2 (es) | Forjado para plantas de construcción | |
| DE502006005053D1 (de) | Spritzbare akustikmassen | |
| AR064219A1 (es) | Cuerpo moldeado que contiene titanio | |
| ECSP109874A (es) | Nuevos compuestos 892 | |
| DE602006017660D1 (de) | Maskenrohlinge |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |